Tracon Pharma | TalkMarkets

Latest Posts

Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange

Article By: ChinaBio® Today

Saturday, October 8, 2022 2:30 PM EDT

Beijing AIM Vaccine conducted a very small IPO on the Hong Kong exchange, raising just $20 million, which netted the company only $10 million. Interest in the offering was low, with less than 1% of the company shares sold in the offering.

In this article: 6660.HK Also: MRNA, TCON, 1672.HK, 6600.HK, CNTB, 6628.HK

Read

Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal

Article By: ChinaBio® Today

Saturday, November 27, 2021 2:30 PM EDT

In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to acquire Zenas shares up to 15% of Zenas’ equity.

In this article: 600276.SS, XNCR, BGNE, TCON, 2616.HK, 9966.HK, 2096.HK

Read

Week In Review: Hansoh Signs $456 Million Deal For SiRNA Products

Article By: ChinaBio® Today

Saturday, October 16, 2021 1:29 PM EDT

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones.

In this article: BMY, STRO, BGNE, ZLAB, TCON, TWST, 9939.HK, 3692.HK, 226950.KQ, 2256.HK

Read

Week In Review: BeiGene Plans $2.5 Billion IPO On Shanghai Star Exchange

Article By: ChinaBio® Today

Saturday, November 21, 2020 2:25 PM EDT

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. The Beijing company is already listed in Hong Kong and the US, and it raised $2.1 billion in a secondary offering on the Hong Exchange in July of this year.

In this article: BMY, MRK, PFE, SEQUX, AMGN, CELG, BGNE, TCON

Read